OraSure Technologies Appoints Stephen S. Tang, Ph.D. to Its Board of Directors
April 07 2011 - 6:00AM
OraSure Technologies, Inc. (Nasdaq:OSUR), today announced the
appointment of Stephen S. Tang, Ph.D. as a member of the Company's
Board of Directors. Dr. Tang will serve as a Class I Director with
an initial term expiring at the Company's 2013 Annual Meeting of
Stockholders.
"I am very pleased to welcome Stephen Tang, a seasoned
healthcare executive, to our Board of Directors," said Douglas G.
Watson, Chairman of the Board of OraSure Technologies. "The
addition of Stephen to OraSure's Board ensures that the Company
will continue to benefit from a diversity of perspectives and
experience, and we look forward to his contribution."
Dr. Tang has enjoyed a distinguished career in the medical
diagnostic and pharmaceutical industries. He is currently the
President and CEO of The University City Science Center, an urban
research park and business incubator based in Philadelphia, a
position he has held since January 2008. Previously, Dr. Tang
was with Olympus America Inc. from 2005 to 2008, where he served as
the Company's first Group Vice President for Life Science, leading
the North American organization of Olympus' $1 billion global
businesses in in vitro diagnostics, precision microscopes, and
translational research instruments.
Prior to Olympus, Dr. Tang was President, Chief Executive
Officer and a Director of Millennium Cell Inc., a NJ-based energy
technology firm that he led from 2000 to 2004 through its initial
public offering and early commercialization phase. Before his work
at Millennium Cell, Dr. Tang served as Vice President and Managing
Director of the global pharmaceutical and healthcare practice of
A.T. Kearney Inc. from 1996 to 2000.
Dr. Tang received his Bachelor of Science in Chemistry from the
College of William and Mary and his Master of Science and Doctor of
Philosophy in Chemical Engineering from Lehigh University. He also
earned a Master of Business Administration from The Wharton School
of Business at the University of Pennsylvania.
Dr. Tang's appointment coincides with the retirement of Dr. Jack
Goldstein from the Company's Board of Directors. Dr.
Goldstein became a member of the Board in 2006 and has served as
Chairman of the Compensation Committee and as a member of the Audit
Committee.
"On behalf of our shareholders, I want to thank Jack Goldstein
for his significant contributions during his tenure on our Board of
Directors. His strategic perspective and scientific insight
have been extremely valuable during his service on our Board," said
Board Chairman Watson.
About OraSure Technologies
OraSure Technologies develops, manufactures and markets oral
fluid specimen collection devices using proprietary oral fluid
technologies, diagnostic products including immunoassays and other
in vitro diagnostic tests, and other medical devices. These
products are sold in the United States as well as internationally
to various clinical laboratories, hospitals, clinics,
community-based organizations and other public health
organizations, distributors, government agencies, physicians'
offices, and commercial and industrial entities.
For more information on the Company, please go to
www.orasure.com.
The OraSure Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6440
CONTACT: Investor Contact:
Ronald H. Spair
Chief Financial Officer
610-882-1820
investorinfo@orasure.com
Media Contact:
Michael Levey
Zer0 to 5ive for OraSure Technologies
610-223-2632
michael@0to5.com
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jul 2023 to Jul 2024